Login

Neoral 100mg/ml concentrate for oral solution

*
Pharmacy Only: Prescription

  • Company:

    Novartis Ireland Limited

  • Status:

    No Recent Update

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

  • Active Ingredient(s):

    Ciclosporin

    *Additional information is available within the SPC or upon request to the company

Updated on 09 July 2024

File name

Neoral oral soln_REG PIL_NURBA June 2024_clean.pdf

Reasons for updating

  • Change to section 6 - manufacturer

Free text change information supplied by the pharmaceutical company

Manufacturer changed to Novartis Farmacéutica, S.A

Updated on 20 June 2023

File name

Neoral oral soln_REG SPC_PF22-0134_08.06.2023_clean_IPHA.pdf

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 5.3 - Preclinical safety data

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 20 June 2023

File name

Neoral oral soln_REG PIL_PF22-0134_08.06.2023_clean_IPHA.pdf

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines

Updated on 11 January 2023

File name

Neoral oral soln_REG PIL_PF22-0183_09.01.2023_clean_IPHA.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 11 January 2023

File name

Neoral capsules_REG PIL_PF22-0183_09.01.2023_clean_IPHA.pdf

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 11 January 2023

File name

Neoral oral soln_REG SPC_PF22-0183_09.01.2023_clean_IPHA.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 28 July 2022

File name

Neoral oral soln_REG PIL_PF22-0077_26.07.2022_clean_IPHA.pdf

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink

Updated on 28 July 2022

File name

Neoral oral soln_REG SPC_PF22-0077_26.07.2022_clean_IPHA.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 16 November 2021

File name

Neoral OS_REG PIL_PF21-0206_10.11.21_clean.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 31 March 2021

File name

Neoral OS_REG PIL_PF 20-0199_Clean.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product looks like and pack contents

Updated on 31 March 2021

File name

Neoral OS_REG SPC_PF 20-0199_March 2021_IPHA.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 12 October 2020

File name

Neoral 100mg-ml Concentrate for Oral Solution REG SPC PF20-0084 August 2020 clean.pdf

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 12 October 2020

File name

PIL Neoral Oral Sol PF 20-0084 clean 5046993 TBI 2021IPHA.pdf

Reasons for updating

  • Change to section 6 - what the product looks like and pack contents

Updated on 18 March 2020

File name

Neoral Oral Sol REG PIL PF 19-0254 march 2020clean.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Updated on 18 March 2020

File name

Neoral 100mg-ml Concentrate for Oral Solution REG SPC_PF19-0154 clean.pdf

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 16 January 2020

File name

Neoral 100 mgml Oral Solution REG PIL 5041623 IPHA.pdf

Reasons for updating

  • Improved presentation of PIL

Updated on 23 January 2019

File name

IPHA_Neoraloralsolt_5041623_REGPIL TBI_06jan2018.pdf

Reasons for updating

  • New PIL for medicines.ie
  • Change to section 6 - marketing authorisation holder

Updated on 09 August 2018

File name

Neoral 100mg-ml Concentrate for Oral Solution REG SPC_PF18-0198_clean.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 10 May 2018

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 24 September 2015

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 24 September 2015

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 has been updated to clarify the wording in "posology and method of administration".

Updated on 04 March 2015

File name

PIL_8555_69.pdf

Reasons for updating

  • New PIL for new product

Updated on 04 March 2015

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 has been updated to include the following:

Pain of lower extremities

Isolated cases of pain of lower extremities have been reported in association with ciclosporin. Pain of lower extremities has also been noted as part of Calcineurin-Inhibitor Induced Pain Syndrome (CIPS).

Updated on 04 March 2015

Reasons for updating

  • Change to side-effects

Updated on 29 September 2014

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change due to harmonisation of SPC

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Entire SmPC revised following approval of Article 30 referral resulting in harmonisation across all EU countries.

Updated on 11 August 2014

Reasons for updating

  • Change due to harmonisation of PIL

Updated on 13 February 2013

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision

Updated on 26 November 2012

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 has been updated to include a paragraph about the conversion between oral ciclosporin formulations.

 

Section 4.4 and Section 4.8 have been updated to specifically describe PML and BK virus nephropathy in the general statement on infections in patients receiving immunosuppressive therapies.

 

Section 5.1 has been updated to include a sentence about the use of ciclosporin in liver transplant patients HCV+ and HCV-.

Updated on 13 September 2012

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
  • Correction of spelling/typing errors

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Following licence renewal, numerous changes were required to the SmPC after IMB assessment.

Updated on 29 August 2012

Reasons for updating

  • Change of manufacturer

Updated on 29 July 2011

Reasons for updating

  • Change to date of revision

Updated on 17 April 2007

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 14 December 2006

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.1 - 4.6 and 5.1, 5.3. Update were made to align the National Prescribing Informtion with the Company Core Data Sheet.

Updated on 22 May 2006

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 17 May 2005

Reasons for updating

  • Improved electronic presentation

Updated on 16 May 2005

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 26 August 2004

Reasons for updating

  • New PIL for medicines.ie

Updated on 02 July 2003

Reasons for updating

  • New SPC for medicines.ie

Legal category:Product subject to medical prescription which may be renewed (B)